SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is heavily trending after a disappointing forward outlook sparked a fierce debate among investors, with many anticipating further declines due to weak guidance. However, a significant portion of the community views the sharp pullback as an overreaction and a strategic buying opportunity, citing strong underlying demand and long-term potential in its foundry initiatives.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending due to recent news of its partnership with Fluor and WSP to advance the Round Top rare earth project, complemented by significant financial backing from the French government for a new European metals and alloys production facility. The community is actively discussing the company's strengthening position in establishing an integrated, non-Chinese rare earth supply chain, fueled by broader geopolitical demand for critical minerals.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending, fueled by its pemvidutide receiving Breakthrough Therapy Designation for MASH, igniting robust speculation about potential acquisitions or partnerships within the competitive GLP-1 and liver disease sector. The community is actively debating the stock's future, with many anticipating a significant rerating amidst increased trading volume, while a vocal segment raises concerns about previous rumors and ongoing legal scrutiny regarding trial data integrity.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing a massive surge as the community passionately anticipates reaching the $100 mark, driven by intense short squeeze narratives and mounting concerns over physical silver shortages. Bulls are largely dismissing calls for a pullback, highlighting strong industrial demand from sectors like solar and EVs, coupled with broader de-dollarization trends and inflation fears, as key catalysts.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending following reports of its finalized deal to establish a U.S. joint venture with TikTok, positioning Oracle to manage U.S. user data and take an equity stake. This development is driving significant community discussion, with many anticipating a substantial upside from Oracle's expanded role in a major consumer platform and its long-term cloud and AI infrastructure growth, while others express caution given the stock's recent volatility and existing debt concerns.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is a top trending stock, driven by an unprecedented surge in trading volume and substantial institutional absorption of a major shareholder's sell-off, which the community sees as a strong vote of confidence. Investors are actively discussing the company's crucial role in the burgeoning space and defense sectors, pointing to its diversified contracts and innovative infrastructure as catalysts for significant future growth. This strong bullish sentiment persists despite ongoing conversations about potential share dilution.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending after releasing positive long-term data for its personalized cancer vaccine, developed in partnership, which demonstrated a significant reduction in melanoma recurrence or death risk. This substantial scientific validation has ignited strong bullish community sentiment, with many anticipating a significant short squeeze and a re-evaluation of the company's future growth potential beyond its initial vaccine achievements.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp. is trending following its Memorandum of Understanding with the Government of Gujarat and Kaynes SemiCon to establish India's first Post-Quantum Cryptography semiconductor center, underscoring its crucial role in the evolving quantum security landscape. Community discussions are highly bullish, fueled by CEO Carlos Moreira's presentations at Davos emphasizing the immediate need for quantum-safe chips to protect against advanced threats posed by AI and quantum computing. This has generated significant anticipation for the company's growth and a potential short squeeze.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to exceptionally high-grade silver drill results from its Vortex system and a surging silver market, fueling speculation around its resource potential. The community is actively discussing the stock's significant short interest, anticipating a potential squeeze, and noting ongoing accumulation by prominent investors. This activity, combined with broader bullish sentiment in precious metals, positions the company for continued conversation and scrutiny as an updated resource report is awaited.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies (ASTI) is generating significant community buzz, driven by comments from Elon Musk regarding the need for solar-powered AI data centers in space. The company's flexible thin-film solar technology and strategic partnerships in defense and space are key discussion points, as investors weigh high upside potential and short squeeze speculation against concerns about historical dilution and company fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

In the latest trading session, Novavax (NVAX) closed at $9.71, marking a -1.97% move from the previous day.

<ul class="summary-bullets"><li>Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year.</li><li>Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.</li><li>Retail sentiment on Stocktwits was 'extremely bullish' for both stocks, with message activity sharply higher over the past year.</li></ul>Wall Street is&nbsp;a bit&nbsp;split on Moderna and Novavax, with analysts favoring upside in one name even as the other has outperformed over the past year.<h2 class="st-heading-2">Analysts Favor Novavax Over Moderna</h2>Koyfin data shows analysts assigning greater upside to Novavax than Moderna based on consensus price targets.Moderna shares were last trading around $49.81 on Wednesday, but Wall Street’s expectations remain cautious. The stock’s average 12-month price target is $37.40, a 25% downside from current levels. Among the 24 analysts covering the company, the overall view sits at ‘Hold’, with two ‘Strong Buy’, two ‘Buy’, 17 ‘Hold’, one ‘Sell’, and two ‘Strong Sell’ ratings, giving Moderna an overall ‘Hold’ rating.Meanwhile, Novavax last closed at $9.9 on Wednesday, and analysts see room for gains. The stock’s average 12-month price target of $12.89 points to a 30% upside&nbsp;from current levels. Among the nine analysts tracking the company, five rate it ‘Buy’, one ‘Hold’, one ‘Sell’, and two ‘Strong Sell’, giving Novavax an overall ‘Buy’ rating.Over the past 12 months,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax shares</a>&nbsp;have been up about 12%, while&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> has gained roughly 39%.<h2 class="st-heading-2">Moderna Faces Analyst Caution</h2>On Tuesday,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-still-worth-37-less-after-cancer-vaccine-data-bof-a-s-new-price-target-keeps-retail-traders-cautious/cmUDauIR4OV">Bank of America Securities raised its price target to $27 from $24</a> while keeping an ‘Underperform’ rating, implying a 37% downside based on the stock’s prior close near $43.The update followed the release of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">five-year follow-up data</a> for Moderna’s personalized cancer vaccine Intismeran Autogene, developed with Merck and used alongside Keytruda in patients with high-risk melanoma. Moderna and Merck said patients receiving the combination showed a 49% lower risk of cancer recurrence or death compared with Keytruda alone.&nbsp;Earlier this month, UBS downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $34 from $40, implying about 32% downside from its last close.&nbsp;Moderna expects regulatory approvals this year for a standalone flu vaccine and a COVID-19/flu combination shot, though not in time for the 2026 respiratory season, with a potential boost in 2027. The company also expects key trial data in 2026, including late-stage norovirus results and mid-stage melanoma data.&nbsp;<h2 class="st-heading-2">Novavax In Focus</h2>This week, Novavax&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nvax-stock-rising-premarket-pfizer-matrix-m-deal/cmUumrjR4aq">signed a non-exclusive licensing deal with Pfizer</a> for up to two disease areas using its Matrix-M adjuvant. The deal includes a $30 million upfront payment, as well as the possibility of up to $500 million in development and sales milestones, and tiered royalties in the high mid-single-digit range.&nbsp;That deal followed Novavax handing over U.S. and European rights to its Covid-19 vaccine candidate Nuvaxovid to Sanofi in November for undisclosed upfront payments and possible milestones. The deal also opens the door&nbsp;to future royalties. Novavax also has deals with Takeda and the Serum Institute of India.Novavax has pushed its profitability target to 2028 as Covid-19 vaccine demand remains under pressure, while activist investor Shah Capital, which holds about 8.3%, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-faces-retail-backlash-as-shah-capital-warns-of-proxy-fight-and-presses-for-a-sale/cLPBFk7REdt">urged the board to review strategic alternatives</a>, including a potential sale.<h2 class="st-heading-2">Regulatory Backdrop</h2>Uncertainty over regulatory approval also looms for both companies. Shares of Moderna and Novavax fell in December after an FDA memo to staff, which did not name a manufacturer, warned of safety problems with vaccines that could lead to tougher approval standards.Novavax’s COVID-19 vaccine has full FDA approval with age- and risk-level-based restrictions, while Moderna's COVID-19 vaccines have full licensure across broader age groups.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment toward Moderna was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 3% and message activity more than doubling over the past 12 months.<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_124327497e.webp" alt="mrna ss.png" width="971" height="142"><figcaption>MRNA sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure>On the other hand, retail sentiment toward Novavax was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 5% and message activity surging more than 600% over the past 12 months.<figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_ec285c2653.webp" alt="nvax ss.png" width="969" height="138"><figcaption>NVAX sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine safety.

Equity

Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) saw unusually large options trading activity on Wednesday. Investors acquired 24,027 call options on the stock. This represents an increase of...

Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer

NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties from Pfizer.

Novavax (NASDAQ:NVAX) Stock Price Up 8% - Still a Buy?

Novavax (NASDAQ:NVAX) Trading Up 8% - Should You Buy...

Novavax's (NVAX) Buy Rating Reiterated at BTIG Research

BTIG Research restated a "buy" rating and issued a $19.00 price objective on shares of Novavax in a research report on Tuesday...

Novavax Shares Rise After Licensing Deal With Pfizer

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for Matrix-M adjuvant.read more...

<ul class="summary-bullets"><li>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones.</li><li>Matrix-M adjuvant is a proprietary vaccine ingredient, used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets.</li><li>Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.</li></ul>Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market trading on Tuesday after the company signed a licensing agreement with Pfizer, granting the pharmaceutical giant non-exclusive rights to use Novavax’s Matrix-M adjuvant in up to two disease areas.Matrix-M adjuvant is a proprietary vaccine ingredient that improves the body’s immune response. It is made from naturally derived compounds and is used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets, according to Novavax.<h2 class="st-heading-2">What Is The Novovax-Pfizer Deal?</h2>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones. Novavax is also eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.Under the agreement, Pfizer will take full responsibility for the development and commercialization of its products, while Novavax will supply the Matrix-M adjuvant. The partnership strengthens Novavax’s long-term revenue potential.This comes after Novavax completed the transfer of U.S. and European marketing authorizations for its COVID-19 vaccine, Nuvaxovid, to Sanofi in November. The move resulted in a second $25 million milestone payment to Novavax, following the completion of the European Union marketing authorization transfer in October 2025.Novavax is expected to receive additional milestone payments and royalties tied to Nuvaxovid, Sanofi-developed combination products, and new vaccines that use Novavax’s Matrix-M adjuvant. Novavax also has long-standing partnerships with Japan’s Takeda and the Serum Institute of India.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/NVAX">NVAX</a> on Stocktwits remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes. NVAX was also among the top three trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/NVAX_jpg_1f4183eedd.webp" alt="NVAX.jpg">One bullish user said that the stock is undervalued.<stembedurl>https://stocktwits.com/ejaXstoXX/message/642272237</stembedurl>Another user was bullish about Matrix-M’s market potential.<stembedurl>https://stocktwits.com/P38FTD/message/642271830</stembedurl>The stock has declined around 6% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-ivf-stock-soaring-premarket/cmUum0oR4ap">INVO Fertility’s 350% Spike Puts Microcap IVF Stocks Back On Retail Radar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It?

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology

Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms of the agreement...

Novavax Announces Entering into a License Agreement with Pfizer

Novavax Announces Entering into a License Agreement with Pfizer Novavax Announces Entering into a License Agreement with Pfizer PR Newswire GAITHERSBURG, Md., Jan. 20, 2026 Non-exclusive license...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Adding shares on dips

Holding, no changes

Trading calls/puts

Watching only

$NVAX is trending hard after the Pfizer licensing headline, but price action is still choppy. What’s your move from here?

How are you playing $NVAX after the $PFE / Matrix-M deal?

Stocktwits

Novavax Inc

Pfizer Inc

Stocktwits Polls

Traders are actively discussing a potential short squeeze with high short interest (55M shares) and the exhaustion of borrowable shares, predicting an explosive upward movement.

Excitement surrounds Matrix-M adjuvant technology, with its recent validation by Pfizer suggesting its potential to become a standard, highly effective component in many future vaccines.

Traders are reacting to Moderna's decision to halt Phase 3 vaccine trials, speculating that mRNA technology is losing favor and positioning NVAX as a key player in the vaccine market.

Discussions highlight the significance of recent deals with Pfizer and Sanofi, with users eagerly anticipating further strategic partnerships for vaccine development and combination products.

Mixed sentiment surrounds CEO John Jacobs, with some criticizing his impact on stock price and communication, while others acknowledge recent partnership wins and anticipate future "surprises."

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.49	--	--	N/A
Q3 '25	-$1.20	-$1.25	-4.49%	MISSED
Q2 '25	-$0.04	$0.62	1849.19%	BEAT
Q1 '25	-$0.42	$2.93	792.13%	BEAT
Q4 '24	-$0.43	-$0.51	-18.60%	MISSED

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NVAX News

NVAXNovavax Inc